Page 1157 - Williams Hematology ( PDFDrive )

1132 Part VIII: Monocytes and Macrophages Chapter 72: Gaucher Disease and Related Lysosomal Storage Diseases 1133

97. Shoenfeld Y, Beresovski A, Zharhary D, et al: Natural autoantibodies in sera of patients 127. Weinreb NJ, Aggio MC, Andersson HC, et al; International Collaborative Gaucher
with Gaucher’s disease. J Clin Immunol 15:363, 1995. Group (ICGG): Gaucher disease type 1: Revised recommendations on evaluations and
98. Hollak CE, van Weely S, van Oers MH, Aerts JM: Marked elevation of plasma chitotri- monitoring for adult patients. Semin Hematol 41:15, 2004.
osidase activity. A novel hallmark of Gaucher disease. J Clin Invest 93:1288, 1994. 128. Sidransky E, Pastores GM, Mori M: Dosing enzyme replacement therapy for Gaucher
99. Boot RG, Verhoek M, de Fost M: Marked elevation of the chemokine CCL18/PARC disease: Older, but are we wiser? Genet Med 11:90, 2009.
in Gaucher disease: A novel surrogate marker for assessing therapeutic intervention. 129. Zimran A, Ilan Y, Elstein D: Enzyme replacement therapy for mild patients with
Blood 103:33, 2004. Gaucher disease. Am J Hematol 84:202, 2009.
100. Rolfs A, Giese AK, Grittner U, et al: Glucosylsphingosine is a highly sensitive and spe- 130. Cox T, Lachmann R, Hollak C, et al: Novel oral treatment of Gaucher’s disease with
cific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet
a non-Jewish, Caucasian cohort of Gaucher disease patients. PLoS One 8:e79732, 2013. 355:1481, 2000.
101. Gielchinsky Y, Elstein D, Green R: High prevalence of low serum vitamin B12 in a 131. Radin NS: Chemical models and chemotherapy in the sphingolipidoses, in Current
multi-ethnic Israeli population. Br J Haematol 115:707, 2001. Trends in Sphingolipidoses and Allied Disorders, edited by Volk BW, Schneck L, p 453.
102. Mikosch P, Reed M, Stettner H, et al: Patients with Gaucher disease living in England Plenum Press, New York, 1976.
show a high prevalence of vitamin D insufficiency with correlation to osteodensitome- 132. Heitner R, Elstein D, Aerts J, et al: Low-dose N-butyldeoxynojirimycin (OGT 918) for
try. Mol Genet Metab 96:113, 2009. type I Gaucher disease. Blood Cells Mol Dis 28:127, 2003.
103. Beutler E, Kuhl W: The diagnosis of the adult type of Gaucher’s disease and its carrier 133. Elstein D, Dweck A, Attias D, et al: Oral maintenance clinical trial with miglustat for
state by demonstration of deficiency of beta-glucosidase activity in peripheral blood type I Gaucher disease: Switch from or combination with intravenous enzyme replace-
leukocytes. J Lab Clin Med 76:747, 1970. ment. Blood 110:2296, 2007.
104. Rudensky B, Paz E, Altarescu G, Raveh D et al: Fluorescent flow cytometric assay: A 134. Lukina E, Watman N, Arreguin EA, et al: A phase 2 study of eliglustat tartrate (Genz-
new diagnostic tool for measuring beta-glucocerebrosidase activity in Gaucher disease. 112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood 116:893,
Blood Cells Mol Dis 30:97, 2003. 2010.
105. Beutler E, Saven A: Misuse of marrow examination in the diagnosis of Gaucher disease. 135. Lukina E, Watman N, Arreguin EA, et al: Improvement in hematological, visceral, and
Blood 76:646, 1990. skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-
106. Zhang CK, Stein PB, Liu J, et al: Genome-wide association study of N370S homozygous 112638) treatment: 2-year results of a phase 2 study. Blood 116:4095, 2010.
Gaucher disease reveals the candidacy of CLN8 gene as a genetic modifier contributing 136. Lukina E, Watman N, Dragosky M, et al: Eliglustat, an investigational oral therapy for
to extreme phenotypic variation. Am J Hematol 87:377, 2012. Gaucher disease type 1: Phase 2 trial results after 4 years of treatment. Blood Cells Mol
107. Lun FM, Tsui NB, Chan KC, et al: Noninvasive prenatal diagnosis of monogenic dis- Dis 53:274, 2014.
eases by digital size selection and relative mutation dosage on DNA in maternal plasma. 137. Fan JQ: A contradictory treatment for lysosomal storage disorders: Inhibitors enhance
Proc Natl Acad Sci U S A 105:19920-5, 2008. mutant enzyme activity. Trends Pharmacol Sci 24:355, 2003.
108. Itzchaki M, Lebel E, Dweck A, et al: Orthopedic considerations in Gaucher disease 138. Ron I, Horowitz M: ER retention and degradation as the molecular basis underlying
since the advent of enzyme replacement therapy. Acta Orthop Scand 75:641, 2004. Gaucher disease heterogeneity. Mol Genet Metab 93:426, 2008.
109. Wenstrup RJ, Bailey L, Grabowski GA, et al: Gaucher disease: Alendronate disodium 139. Sun Y, Liou B, Xu YH, et al: Ex vivo and in vivo effects of isofagomine on acid
improves bone mineral density in adults receiving enzyme therapy. Blood 104:1253, β-glucosidase variants and substrate levels in Gaucher disease. J Biol Chem 287:4275,
2004. 2012.
110. Rodgers GP, Lessin LS: Recombinant erythropoietin improves the anemia associated 140. Goker-Alpan O: Commentary on “Pilot study using ambroxol as a pharmacological
with Gaucher’s disease. Blood 73:2228, 1989. chaperone in type 1 Gaucher disease” by Zimran et al. Blood Cells Mol Dis 50:138, 2013.
111. Grabowski GA, Barton NW, Pastores G, et al: Enzyme therapy in type 1 Gaucher dis- 141. Zimran A, Altarescu G, Elstein D: Pilot study using ambroxol as a pharmacological
ease: Comparative efficacy of mannose-terminated glucocerebrosidase from natural chaperone in type 1 Gaucher disease. Blood Cells Mol Dis 50:134, 2013.
and recombinant sources. Ann Intern Med 122:33, 1995. 142. Ayto RM, Hughes DA, Jeevaratnam P, et al: Long-term outcomes of liver transplanta-
112. Zimran A, Altarescu G, Phillips M, et al: Phase I/II and extension study of velaglucerase tion in type 1 Gaucher disease. Am J Transplant 10:1934, 2010.
alfa (Gene-Activated Human Glucocerebrosidase) replacement therapy in adults 143. Mistry P, Zimran A: Type I Gaucher disease—Clinical features, in Gaucher Disease,
TM
with type 1 Gaucher disease: 48 Month experience. Blood 115:4651, 2010. edited by Futerman AH, Zimran A, p 155. CRC Press, Boca Raton, FL, 2007.
113. Zimran A, Brill-Almon E, Chertkoff R, et al: Pivotal trial with plant-cell-expressed 144. Taddei TH, Kacena KA, Yang M, et al: The underrecognized progressive nature of
recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement ther- N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol
apy for Gaucher disease. Blood 118:5767, 2011. 84:208, 2009.
114. Weinreb NJ, Charrow J, Andersson HC, et al: Effectiveness of enzyme replacement 145. Weinreb NJ, Deegan P, Kacena KA, et al: Life expectancy in Gaucher disease type 1. Am
therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: A J Hematol 83:896, 2008.
report from the Gaucher Registry. Am J Med 113:112, 2002. 146. Niemann A: Ein unbekanntes Krankheitsbild. Jahrbuch Kinderheilkunde 79:1, 1914.
115. Zimran A, Bembi B, Pastores G: Enzyme replacement therapy for type I Gaucher dis- 147. Pick L: Uber die lipoidzellige Splenhepatomegalie Typus Niemann-Pick als Stoffwech-
ease, in Gaucher Disease, edited by Futerman AH, Zimran A, p 341. CRC Press, Boca selerkrankung. Med Klin 23:1483, 1927.
Raton, FL, 2007. 148. Brady RO, Kanfer JN, Mock MB, et al: The metabolism of sphingomyelin II. Evidence
116. Grabowski GA, Kacena K, Cole JA, et al: Dose-response relationships for enzyme of an enzymatic deficiency in Niemann-Pick disease. Proc Natl Acad Sci U S A 55:366,
replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease 1966.
type 1. Genet Med 11:92, 2009. 149. Schuchman EH, Desnick RJ: Niemann-Pick disease types A and B: Acid sphingomyeli-
117. Maas M, Hollak CE, Akkerman EM, et al: Quantification of skeletal involvement in nase deficiencies, in The Metabolic and Molecular Bases of Inherited Disease, 7th ed, edited
adults with type I Gaucher’s disease: Fat fraction measured by Dixon quantitative by Scriver CR, Beaudet AL, Sly WS, Valle D, p 2601. McGraw-Hill, New York, 1995.
chemical shift imaging as a valid parameter. AJR Am J Roentgenol 179:961, 2002. 150. Pentchev PG, Vanier MT, Suzuki K, et al: Niemann-Pick disease type C: A cellular choles-
118. Altarescu G, Hill S, Wiggs E, et al: The efficacy of enzyme replacement therapy in terol lipidosis, in The Metabolic and Molecular Bases of Inherited Disease, 7th ed, edited by
patients with chronic neuronopathic Gaucher’s disease. J Pediatr 138:539, 2001. Scriver CR, Beaudet AL, Sly WS, Valle D, p 2625. McGraw-Hill, New York, 1995.
119. Zimran A, Elstein D: No justification for very high-dose enzyme therapy for patients 151. Greer WL, Riddell DC, Murty S, et al: Linkage disequilibrium mapping of the Nova
with type III Gaucher disease. J Inherit Metab Dis 30:843, 2007. Scotia variant of Niemann-Pick disease. Clin Genet 55:248, 1999.
120. Starzyk K, Richards S, Yee J, et al: The long-term international safety experience of 152. Schuchman EH, Miranda SR: Niemann-Pick disease: Mutation update, genotype/phe-
imiglucerase therapy for Gaucher disease. Mol Genet Metab 90:157, 2007. notype correlations, and prospects for genetic testing. Genet Test 1:13, 1997.
121. Langeveld M, de Fost M, Aerts JM, et al: Overweight, insulin resistance and type II 153. Simonaro CM, Desnick RJ, McGovern MM, et al: The demographics and distribution
diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy. of type B Niemann-Pick disease: Novel mutations lead to new genotype/phenotype cor-
Blood Cells Mol Dis 40:428, 2008. relations. Am J Hum Genet 71:1413, 2002.
122. Zimran A, Hollak CEM, Abrahamov A, et al: Home treatment with intravenous 154. Wenger DA, Barth G, Githens JH: Nine cases of sphingomyelin lipidosis, a new variant
enzyme replacement therapy for Gaucher disease: An international collaborative study in Spanish-American children. Juvenile variant of Niemann-Pick Disease with foamy
of 33 patients. Blood 82:1107, 1993. and sea-blue histiocytes. Am J Dis Child 131:955, 1977.
123. Granovsky-Grisaru S, Belmatoug N, vom Dahl S, et al: The management of pregnancy 155. Millat G, Marçais C, Rafi MA, et al: Niemann-Pick C1 disease: The I1061T substitution
in Gaucher disease. Eur J Obstet Gynecol Reprod Biol 156:3, 2011. is a frequent mutant allele in patients of Western European descent and correlates with
124. Elstein D, Hughes D, Goker-Alpan O, et al: Outcome of pregnancies in women receiv- a classic juvenile phenotype. Am J Hum Genet 65:1321, 1999.
ing velaglucerase alfa for Gaucher disease. J Obstet Gynaecol Res 40:968, 2014. 156. Patterson MC, Vanier MT, Suzuki K, et al: Niemann-Pick disease type C: A lipid traf-
125. Zimran A, Pastores GM, Tylki-Szymanska A, et al: Safety and efficacy of velaglucerase ficking disorder, in The Metabolic and Molecular Bases of Inherited Disease, 8th ed,
alfa in Gaucher disease type 1 patients previously treated with imiglucerase. Am J edited by Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B,
Hematol 88:172, 2013. p 3611. McGraw-Hill, New York, 2001.
126. Pastores GM, Petakov M, Giraldo P, et al: A Phase 3, multicenter, open-label, switchover 157. Takahashi T, Suchi M, Desnick RJ, et al: Identification and expression of five mutations
trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombi- in the human acid sphingomyelinase gene causing types A and B Niemann-Pick dis-
nant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease pre- ease. Molecular evidence for genetic heterogeneity in the neuronopathic and non-neu-
viously treated with imiglucerase. Blood Cells Mol Dis 2014 Jun 17 [Epub ahead of print] ronopathic forms. J Biol Chem 267:12552, 1992.

Kaushansky_chapter 72_p1121-1134.indd 1132 9/17/15 3:53 PM